Data Insights

FT-522 by Fate Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - FT-522 in Primary Mediastinal B-Cell Lymphoma

Data Insights

FT-522 by Fate Therapeutics for Follicular Lymphoma: Likelihood of Approval

FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Data Insights

FT-522 by Fate Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - FT-522 in Diffuse Large B-Cell Lymphoma

Data Insights

FT-819 by Fate Therapeutics for Systemic Lupus Erythematosus: Likelihood of Approval

FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in Systemic Lupus Erythematosus

Data Insights

FT-819 by Fate Therapeutics for Non-Hodgkin Lymphoma: Likelihood of Approval

FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in Non-Hodgkin Lymphoma

Data Insights

FT-522 by Fate Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

FT-522 is under clinical development by Fate Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...

Data Insights

FT-819 by Fate Therapeutics for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...

Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

FT-825 by Fate Therapeutics for Solid Tumor: Likelihood of Approval

FT-825 is under clinical development by Fate Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - FT-825 in Solid Tumor

Data Insights

Risk adjusted net present value: What is the current valuation of Fate Therapeutics's FT-576?

FT-576 is a gene-modified cell therapy commercialized by Fate Therapeutics, with a leading Phase I program in Relapsed Multiple Myeloma....

Net Present Value Model: Fate Therapeutics Inc's FT-576

Data Insights

Risk adjusted net present value: What is the current valuation of Fate Therapeutics's FT-819?

FT-819 is a gene-modified cell therapy commercialized by Fate Therapeutics, with a leading Phase I program in B-Cell Acute Lymphocytic...

Net Present Value Model: Fate Therapeutics Inc's FT-819

Data Insights

FT-819 by Fate Therapeutics for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

FT-819 is under clinical development by Fate Therapeutics and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...

Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in Relapsed Chronic Lymphocytic Leukemia (CLL)